Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
aflibercept + verteporfin
- Development stage
- Phase 4
- Lead developer
- Regeneron Pharmaceuticals
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes, Small Molecules
- Administration
- Intravitreal, Intravenous
01
Overview
A combination therapy consisting of intravitreal aflibercept injection (anti-VEGF agent) and verteporfin photodynamic therapy (PDT). This dual approach targets different aspects of retinal vascular diseases - aflibercept inhibits VEGF to reduce abnormal blood vessel growth and leakage, while PDT with verteporfin selectively damages abnormal blood vessels through light activation of the photosensitizer. The combination is primarily used for treating polypoidal choroidal vasculopathy (PCV) and neovascular age-related macular degeneration (AMD).
02
Targets
LGALS1 (Galectin-1)Membrane lipids/proteins in choroidal neovascular tissuePGF (Placental Growth Factor)VEGFA (Vascular endothelial growth factor A)VEGFB (Vascular endothelial growth factor B)
Beyond the preview
Go deeper on aflibercept + verteporfin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on aflibercept + verteporfin.